Multiple Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of KSHN001034 in Healthy Postmenopausal Female Volunteers

NCT06995482 | Recruiting Phase 1 DMC FDA Drug

• 1 other identifier: CE-24-06
• Study Type: interventional
• Target: 40
• Locations: 2 countries
• Sites: 2

Brief Summary

The goal of this clinical trial is to evaluate if KSHN001034 demonstrates safety, tolerability, and a comparable pharmacokinetic (PK) profile to the reference product, Faslodex® (fulvestrant), which is used for the treatment of hormone receptor-positive breast cancer. Participants will: Receive either the test product (KSHN001034) or the reference product (Faslodex®) administered intramuscularly (IM) or subcutaneously (SC) at doses of low, medium, or high , with doses conducted in 5 cohorts and these participants will be healthy postmenopausal female volunteers. Dosing will be administered in a sequential cohort-wise manner across five cohorts, with DSMB oversight for safety monitoring and dose escalation. Primary Endpoint: Safety and tolerability will be assessed based on the occurrence, severity, and relationship of adverse events (AEs), including serious adverse events (SAEs). Secondary Endpoint: Pharmacokinetic (PK) parameters will be evaluated, including Cmax (maximum concentration), Tmax (time to maximum concentration), AUC (area under the curve), and T1/2 (half-life).

Conditions

Healthy Postmenopausal Women

Outcome Measures

Primary Outcomes (1)

• Number of participants with treatment-related Adverse events as assessed by CTCAE v5.0

  Adverse events reported after dosing will be evaluated

  up to 36 days after dosing

Secondary Outcomes (4)

• Pharmacokinetic parameter

  upto day 36 after dosing

• Pharmacokinetic parameter

  upto day 36 after dosing

• Pharmacokinetic parameter

  up to 36 days after dosing

• Pharmacokinetic parameter

  up to 36 days after dosing

Study Arms (5)

Cohort 1

EXPERIMENTAL

Drug: KSHN001034; Drug: Fulvestrant

Cohort 2

EXPERIMENTAL

Drug: KSHN001034; Drug: Fulvestrant

Cohort 3

EXPERIMENTAL

Drug: KSHN001034; Drug: Fulvestrant

Cohort 4

EXPERIMENTAL

Drug: KSHN001034; Drug: Fulvestrant

Cohort 5

EXPERIMENTAL

Drug: KSHN001034; Drug: Fulvestrant

Interventions

KSHN001034 DRUG

Test Product: KSHN001034, 5 mL vial containing 113 mg/mL of KSHN001034, equivalent to 100 mg/mL of fulvestrant. Manufactured for Kashiv Biosciences LLC, USA. • 6 subjects will receive low dose of KSHN001034 IM on Days 1, 8, 15, and 22.

Cohort 1

Fulvestrant DRUG

Reference Product: Faslodex® (Fulvestrant), 5 mL pre-filled syringe containing 250 mg/5 mL of fulvestrant, administered as two 5 mL injections (total 500 mg) via intramuscular (IM) injection. Marketed by AstraZeneca. • 2 subjects will receive 500 mg Fulvestrant IM on Days 1 and 15.

Cohort 1; Cohort 2; Cohort 3; Cohort 4; Cohort 5

Eligibility Criteria

• Age: 45 Years - 60 Years
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Able to provide written Informed Consent and communicate with the investigator and comprehend study-related procedures.
• Healthy, postmenopausal females aged 45 to 60 years old (inclusive), as determined by medical history and physical examination.
• Body Mass Index at screening between 18 and 30 kg/m2, inclusive.
• Post-menopausal females (Menopause is defined as the female is either 12 months off menstrual period after the age of 50 years, or 12 months off menstrual period after the age of 45 years and FSH \> 40 mIU/mL Note: Amenorrhea should not be due to lactation).
• Participant must be healthy on the basis of their medical history, a physical examination, vital signs, and 12-lead Electrocardiogram (ECG) performed during screening and as determined by the Principal Investigator (PI).
• Hemoglobin at screening and Day (-1) ≥ 11 g/dl
• Ability to communicate well and to comply with the requirements of the entire study.
• Adequate venous access and can able to give required blood samples.

You may not qualify if:

• History or presence of cardiovascular, pulmonary, hepatic, renal, hematologic, coagulation, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease or any other clinical significant abnormalities during screening investigations which, in the opinion of the PI, may either put the participant at risk because of participation in the study, or influence the results or the participant's ability to participate in the study.
• Evidence of organ dysfunction \[e.g. liver dysfunction; ≥ Upper Limit of Normal (ULN) for ALT, AST or ALP or renal dysfunction (\<90 mL/min of creatinine clearance by Cockroft-Gault formula\] or any clinically significant abnormalities in other clinical laboratory parameters at screening as determined by the investigator.
• QTc (Bazzett) interval ≥450 ms on ECG at screening.
• Any major surgery requiring general anesthesia within 3 months prior to screening.
• Known or suspected history of alcohol dependency or addictive substance use, as judged by the investigator Note: Participants will be required to abstain from recreational use of soft addictive substances (such as marijuana) within 2 weeks or hard addictive substances (such as cocaine, phencyclidine, crack, opioid derivatives including heroin, and amphetamine derivatives) within 2 months prior to screening
• History or presence of malignancy in the last 5 years
• Positive testing for human immunodeficiency virus (HIV I or II), hepatitis B (hepatitis B surface antigen \[HBsAg\]), or hepatitis C (Anti-HCV antibody) at screening.
• Received or intending to receive a vaccination in the two weeks prior to dosing, or anytime during study participation.
• Donated blood within 60 days of screening or otherwise experienced blood loss of \>250 mL within the same period.
• Presence of low platelet count (i.e. lower than LLN), bleeding issues or family history of bleeding disorders.
• Participant has a history of hypersensitivity to heparin as checked at screening.
• History of hypersensitivity or idiosyncratic reaction to test drug or any drug chemically similar to the drug under investigation or any of the excipients.
• The participant has any estrogen- dependent conditions including benign breast conditions
• The participant has a history of osteoporosis or any disease affecting bone or steroid metabolism.
• Intolerance to/ fear of venipuncture, needles, or blood draws.

Sponsors & Collaborators

• Kashiv BioSciences, LLC: lead
• Eric Solutions LLC: collaborator
• Clinexcel Research, Ahmedabad, India: collaborator

Study Sites (2)

Floridian Clinical Research LLC

Miami Lakes, Florida, 33016, United States

RECRUITING

Synergen Bio Pvt. Ltd.

Pune, Maharashtra, 411003, India

RECRUITING

MeSH Terms

Interventions

Fulvestrant

Intervention Hierarchy (Ancestors)

Estradiol; Estrenes; Estranes; Steroids; Fused-Ring Compounds; Polycyclic Compounds; Estradiol Congeners; Gonadal Steroid Hormones; Gonadal Hormones; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists

Central Study Contacts

Pawan Singh

CONTACT

+91 7666522355; pawan.singh@kashivindia.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 19, 2025
• First Posted: May 29, 2025
• Study Start: August 18, 2025
• Primary Completion: May 1, 2026
• Study Completion (Estimated): June 1, 2026
• Last Updated: February 12, 2026

Record last verified: 2026-02

Locations

IN (1); US (1)